APA (7th ed.) Citation

Yabe, D., Iizuka, K., Baxter, M., Watanabe, D., & Kaneto, H. (2021). iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial. Wiley.

Chicago Style (17th ed.) Citation

Yabe, Daisuke, Katsumi Iizuka, Mike Baxter, Daisuke Watanabe, and Hideaki Kaneto. IGlarLixi Reduces Residual Hyperglycemia in Japanese Patients with Type 2 Diabetes Uncontrolled on Basal Insulin: A Post‐hoc Analysis of the LixiLan JP‐L Trial. Wiley, 2021.

MLA (9th ed.) Citation

Yabe, Daisuke, et al. IGlarLixi Reduces Residual Hyperglycemia in Japanese Patients with Type 2 Diabetes Uncontrolled on Basal Insulin: A Post‐hoc Analysis of the LixiLan JP‐L Trial. Wiley, 2021.